Current Report Filing (8-k)
06 Mars 2023 - 10:22PM
Edgar (US Regulatory)
false000185027000018502702023-03-062023-03-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 06, 2023 |
PROKIDNEY CORP.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Cayman Islands |
001-40560 |
98-1586514 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
2000 Frontis Plaza Blvd. Suite 250 |
|
Winston-Salem, North Carolina |
|
27103 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 336 999-7029 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Class A ordinary shares, $0.0001 par value per share |
|
PROK |
|
The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
ProKidney Corp. (the “Company”) has updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Presentation is available on the Company’s website at https://investors.prokidney.com/news-events/events-and-presentations. The Presentation is also attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
The exhibits filed as part of this Current Report on Form 8-K are listed in the index to exhibits immediately preceding the signature page to this Current Report on Form 8-K, which index to exhibits is incorporated herein by reference.
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
PROKIDNEY CORP. |
|
|
|
|
Date: |
March 6, 2023 |
By: |
/s/ Todd Girolamo |
|
|
|
Todd Girolamo Chief Legal Officer |
Social Capital Suvretta ... (NASDAQ:DNAC)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Social Capital Suvretta ... (NASDAQ:DNAC)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
Real-Time news about Social Capital Suvretta Holdings Corporation III (NASDAQ): 0 recent articles
Plus d'articles sur Prokidney Corp.